Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nürtingen
Clinical trial register · Germany

Clinical Trials in Nürtingen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5060 matching records held by the registry are in this view. Synced 14 Oct 2026, 03:18 UTC
5060
Studies in scope
all four open statuses
2879
Recruiting now
open to new participants
987
Lead sponsors
across recruiting studies
Top sites
Berlin 1589 Hamburg 891 Essen 764 Dresden 713 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC6 Pfizer5 Exelixis3 Aragon Pharmaceuticals, Inc.3 Astellas Pharma Global Development, Inc.2
Site location
Berlin1589 Hamburg891 Essen764 Dresden713 Heidelberg627
All 640 locations
Target enrolment
to

Trials with a site in Nürtingen

40 of 5060 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Hoffmann-La Roche
Phase 2
100
Freiburg im Breisgau, Hamburg, Münster, Nürtingen
2026-03-11
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Dresden, Duisburg, Essen, Hamburg, München, Nürtingen
2025-12-19
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Heidelberg, Nürtingen, Munich, Nuremberg, Regensburg, Hanover, Kiel, Jena
2025-09-30
Recruiting
Pfizer
Phase 3
1,000
Heidelberg, Nürtingen, Ulm, Mettmann, Lübeck, Berlin, Düsseldorf, Hamburg
2025-09-28
Recruiting
Daiichi Sankyo
Phase 2/3
630
Eisleben Lutherstadt, Herne, Nürtingen, Stuttgart
2025-09-26
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Cologne, Herne, Leverkusen, Mannheim, Nürtingen, Regensburg
2025-09-10
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Nürtingen, Heinsberg
2025-08-19
Active, closed
Novartis Pharmaceuticals
Phase 2
168
Düsseldorf, Hamburg, Lübeck, Nürtingen
2025-07-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Nürtingen, Stuttgart, Munich, Nuremberg, Frankfurt am Main, Cologne, Duisburg, Mainz
2025-05-13
Active, closed
Celgene
Phase 3
960
Nürtingen, München, Lübeck, Jena, Bonn, Essen, Hamburg, Heidelberg
2025-03-13
Recruiting
Novartis Pharmaceuticals
Observational
3,250
Baden-Baden, Filderstadt, Freudenstadt, Heidelberg, Heidenheim, Konstanz, Mannheim, Nürtingen
2025-02-20
Recruiting
Pfizer
Phase 3
900
Nürtingen, Tübingen, Münster, Hamburg
2024-10-22
Active, closed
Pfizer
Phase 3
600
Nürtingen, Tübingen, Mettmann, Münster, Hamburg
2024-10-21
Recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
NCT06835218Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
UroTrials Company (GmbH)
Observational
5,000
Freiburg im Breisgau, Heidelberg, Mannheim, Nürtingen, Tübingen, Ulm, Augsburg, Bayreuth
2024-01-29
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Freiburg im Breisgau, Heidelberg, Nürtingen, Munich, Regensburg, Marburg, Göttingen, Bergisch Gladbach
2023-12-18
Active, closed
Janssen Research & Development, LLC
Phase 3
420
Aachen, Augsburg, Cologne, Dresden, Lübeck, München, Nürtingen, Würzburg
2023-08-31
Active, closed
Hoffmann-La Roche
Phase 2
199
Dresden, Hamburg, Hanover, München, Nürtingen, Ulm
2023-04-21
Active, closed
Bayer
Phase 3
985
Mannheim, Nürtingen, Stuttgart, Würzburg, Frankfurt am Main, Braunschweig, Göttingen, Aachen
2023-04-03
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Freiburg im Breisgau, Heidelberg, Nürtingen, Pforzheim, Tübingen, Ulm, Erlangen, Munich
2023-01-16
Active, closed
Eli Lilly and Company
Phase 3
925
Freiburg im Breisgau, Heidelberg, Nürtingen, Ulm, Tübingen, Munich, Frankfurt am Main, Duisburg
2022-04-14
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab
Exelixis
Phase 1
1,394
Essen, Hamburg, Heidelberg, Herne, Jena, München, Nürtingen, Trier
2021-12-14
Active, closed
AstraZeneca
Observational
752
Böblingen, Göttingen, Nürtingen, Osnabrück, Rotenburg (Wümme), Aachen, Amberg, Aschaffenburg
2021-06-15
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
DrugPhase 2
enGene, Inc.
Phase 1/2
350
Cologne, Duisburg, Erlangen, Mettmann, Nürtingen, Tübingen
2021-04-22
Active, closed
Janssen Research & Development, LLC
Phase 2
220
Cologne, Duisburg, Herne, Markkleeberg, Mettmann, Münster, Nuremberg, Nürtingen
2020-12-18
Active, closed
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565HER2-negative Breast Cancer, Triple Negative Breast Cancer
DrugsXeloda·Sacituzumab Govitecan·Paraplatin·Capecitabine
GBG Forschungs GmbH
Phase 3
1,332
Böblingen, Esslingen am Neckar, Freiburg im Breisgau, Karlsruhe, Mannheim, Nürtingen, Reutlingen, Ulm
2020-10-28
Active, closed
Bayer
Phase 3
402
Emmendingen, Freiburg im Breisgau, Mühlacker, Nürtingen, Reutlingen, Tübingen, Erlangen, Braunschweig
2020-10-20
Active, closed
Exelixis
Phase 3
575
Nürtingen, Duisburg, Gütersloh, Münster, Lübeck, Berlin, Hamburg, Hanover
2020-10-19
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Braunschweig, Cologne, Dresden, Duisburg, Hanover, München, Münster, Nürtingen
2020-09-23
Active, closed
AstraZeneca
Phase 3
1,012
Berlin, Duisburg, Hamburg, Herne, Mettmann, Münster, Nuremberg, Nürtingen
2020-07-13
Active, closed
Pfizer
Phase 3
1,068
Duisburg, Frankfurt, Münster, Nürtingen, Tübingen
2019-12-30
Active, closed
RhoVac APS
Phase 2
180
Dresden, Duisburg, Hagenow, Halle, Nürtingen, Tübingen
2019-11-19
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab
Exelixis
Phase 1
325
Nürtingen, Münster, Hamburg
2019-03-20
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Braunschweig, Duisburg, Homburg, Magdeburg, Münster, Nürtingen
2019-01-25
Active, closed
Eli Lilly and Company
Phase 2/3
393
Nürtingen, Tübingen, Holzminden, Cologne, Mettmann, Münster, Wesel, Leipzig
2018-11-26
Active, closed
Pfizer
Phase 3
1,054
Düsseldorf, Hamburg, Heidelberg, Kirchheim, Münster, Nürtingen
2017-12-18
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Nürtingen, Waldshut-Tiengen, Mannheim, Duisburg, Bonn, Hamburg
2016-12-22
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Bonn, Braunschweig, Eisleben Lutherstadt, Hamburg, Hanover, Leipzig, Lübeck, Nürtingen
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Braunschweig, Chemnitz, Dessau, Frankfurt, Gronau, Jena, Münster, Nürtingen
2015-11-19
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Heidelberg, Münster, Nürtingen, Wuppertal
2014-11-26
Recruiting
Praegnant Breast Cancer: Early/Advanced/Metastatic
NCT02338167Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
University Hospital Tuebingen
Observational
13,500
Böblingen, Freiburg im Breisgau, Heidelberg, Karlsruhe, Mannheim, Nürtingen, Tübingen, Ulm
2014-06
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 October 2026. https://priyalifescience.com/clinical-trials-germany/city/n-rtingen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,060 studies in total at the last sync on 14 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Nürtingen.

How many clinical trials are recruiting in Nürtingen?

15 of the 40 studies on this page are recruiting new participants as of the 14 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 25 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nürtingen), 40 studies
PhaseStudiesRecruitingShare
Phase 323657.5%
Phase 27217.5%
Observational4310%
Phase 2/3327.5%
Phase 1215%
Phase 1/2112.5%

Most active sponsors

Lead sponsors with the most studies (Nürtingen)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC62
Pfizer52
Aragon Pharmaceuticals, Inc.30
Exelixis31
Astellas Pharma Global Development, Inc.21
AstraZeneca20
Bayer20
Eli Lilly and Company20
Hoffmann-La Roche21
Merck Sharp & Dohme LLC22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.